SEC Form 4 · accession 0001193125-26-292526
Beam Therapeutics Inc. · BEAM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M. Evans
Officer — CEO · Director
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001745999
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2026 | M | 18,663 | $0.67 | A | 1,065,868 | D | |
| Common Stock | Jun 29, 2026 | M | 6,337 | $1.03 | A | 1,072,205 | D | |
| Common StockF2 | Jun 29, 2026 | S | 13,421 | $35.1336 | D | 1,058,784 | D | |
| Common StockF3 | Jun 29, 2026 | S | 11,579 | $35.9119 | D | 1,047,205 | D | |
| Common Stock | Jun 30, 2026 | M | 25,000 | $1.03 | A | 1,072,205 | D | |
| Common StockF4 | Jun 30, 2026 | S | 23,100 | $34.2633 | D | 1,049,105 | D | |
| Common StockF5 | Jun 30, 2026 | S | 1,900 | $34.8437 | D | 1,047,205 | D | |
| Common Stock | holding | — | — | — | 103,000 | I | By John M. Evans, III 2018 Irrevocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $0.67 | Jun 29, 2026 | M | 18,663 | D | — | May 8, 2028 | Common Stock | 18,663 | 9 | D |
| Stock Option (Right to Buy)F7 | $1.03 | Jun 29, 2026 | M | 6,337 | D | — | Jul 13, 2028 | Common Stock | 6,337 | 230,804 | D |
| Stock Option (Right to Buy)F7 | $1.03 | Jun 30, 2026 | M | 25,000 | D | — | Jul 13, 2028 | Common Stock | 25,000 | 205,804 | D |
Explanation of responses
- F1The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
- F7On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.